Impact of Immunohistochemical PSA and Ki‐67 Expression on Prognosis in Metastatic Castration‐Sensitive Prostate Cancer
International Journal of Urology · 2026
DOI: 10.1111/iju.70368 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Miyaka Umemori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University, Chiba, Japan. Hauptthemen laut MEDLINE: Ki-67 Antigen, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Bone Neoplasms. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background and Objective Treatment selection for metastatic castration‐sensitive prostate cancer (mCSPC) remains challenging, as reliable and practical biomarkers predicting response to androgen receptor pathway inhibitor (ARPI)‐based therapy are limited. We evaluated whether prostate‐specific antigen (PSA) and Ki‐67 expression in diagnostic biopsy specimens can predict oncologic outcomes in patients with mCSPC treated with ARPI–androgen deprivation therapy (ADT) doublet therapy, and whether these biomarkers can guide optimal treatment selection.
Methods
This retrospective multicenter study included 58 patients with mCSPC who received ARPI–ADT doublet therapy between 2018 and 2024. Immunohistochemical staining for PSA and Ki‐67 was performed on diagnostic biopsy specimens. Receiver operating characteristic curve analyses were used to determine optimal cutoff values for predicting progression to castration‐resistant prostate cancer (CRPC). Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models. Exploratory analyses included patients treated with triplet therapy (ADT + docetaxel + darolutamide) or upfront docetaxel.
Results
Low PSA expression, high Ki‐67 expression, and a bone metastasis extent of disease (EOD) score ≥ 3 were independently associated with shorter CRPC‐free survival (CRPC‐FS). Stratification by risk factors (0, 1, or 2) showed a stepwise decline in CRPC‐FS. In exploratory analyses, triplet therapy achieved the longest CRPC‐FS and progression‐free survival 2 among high‐risk patients, whereas no significant differences among treatment modalities were observed in the low‐risk group.
Conclusion
Immunohistochemical PSA and Ki‐67 expression provide practical prognostic information for patients with metastatic castration‐sensitive prostate cancer. Combined assessment with EOD ≥ 3 identifies a high‐risk subgroup with unfavorable clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University, Chiba, Japan.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Atsugi City Hospital, Atsugi, Kanagawa, Japan.
- Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
ORCID-Profile: Fumihiko Urabe, Yu Imai, Kojiro Tashiro, Takahiro Kimura
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Umemori, M., Urabe, F., Iwamoto, Y., Imai, Y., Tashiro, K., Sato, S., Takahashi, H., & Kimura, T. (2026). Impact of Immunohistochemical PSA and Ki‐67 Expression on Prognosis in Metastatic Castration‐Sensitive Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70368
Vancouver
Umemori M, Urabe F, Iwamoto Y, Imai Y, Tashiro K, Sato S, et al. Impact of Immunohistochemical PSA and Ki‐67 Expression on Prognosis in Metastatic Castration‐Sensitive Prostate Cancer. International Journal of Urology. 2026. doi:10.1111/iju.70368
BibTeX
@article{Umemori2026,
author = {Umemori, Miyaka and Urabe, Fumihiko and Iwamoto, Yuya and Imai, Yu and Tashiro, Kojiro and Sato, Shun and Takahashi, Hiroyuki and Kimura, Takahiro},
title = {Impact of Immunohistochemical PSA and Ki‐67 Expression on Prognosis in Metastatic Castration‐Sensitive Prostate Cancer},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70368}
}
EUVIMED